Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sdAb5-based BCMA CAR-T cells
- Development stage
- Preclinical
- Lead developer
- Cima Universidad de Navarra
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
sdAb5-based BCMA CAR-T cells are an experimental second-generation chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) for the treatment of multiple myeloma. Developed by Cima Universidad de Navarra and Nanogrow Biotech, the therapy utilizes a single-domain antibody (sdAb) derived from immunized llamas (clone sdAb5) as the antigen-recognition moiety, coupled with a 4-1BB costimulatory domain. In preclinical xenograft models, sdAb5-based CAR-T cells demonstrated superior antitumoral efficacy and persistence compared to approved BCMA CAR-T therapies like idecabtagene vicleucel and ciltacabtagene autoleucel. The therapy is characterized by a unique Th2 polarization that transitions into CD8+ effector and memory-like cells, enabling robust re-expansion and sustained protection upon tumor rechallenge.
- Other names
- sdAb5-based CAR-T cellssdAb-5-based CAR-T cellssdAb 5-based CAR-T cells
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on sdAb5-based BCMA CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sdAb5-based BCMA CAR-T cells.